US FDA accepts Mylan and Biocon’s proposed biosimilar bevacizumab for review
The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is December 27, 2020
Biocon and Mylan announced that the US…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.